Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Invesco Ltd.

Invesco Ltd. decreased its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 35.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 204,890 shares of the medical device company's stock after selling 112,695 shares during the period. Invesco Ltd. owned about 0.31% of Tandem Diabetes Care worth $7,380,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. AlphaQuest LLC lifted its holdings in Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after buying an additional 541 shares in the last quarter. Jones Financial Companies Lllp raised its stake in shares of Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after acquiring an additional 748 shares in the last quarter. Assetmark Inc. boosted its holdings in shares of Tandem Diabetes Care by 77.5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after purchasing an additional 535 shares during the period. McIlrath & Eck LLC bought a new position in Tandem Diabetes Care in the third quarter worth approximately $52,000. Finally, Smartleaf Asset Management LLC increased its holdings in Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock worth $65,000 after purchasing an additional 1,101 shares during the period.

Insiders Place Their Bets

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on TNDM shares. The Goldman Sachs Group dropped their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Mizuho began coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 target price on the stock. Sanford C. Bernstein cut shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Barclays cut their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, Morgan Stanley lowered Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and lowered their target price for the stock from $45.00 to $22.00 in a report on Wednesday, March 5th. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $43.81.

Tandem Diabetes Care Stock Performance

TNDM stock traded up $0.08 during trading on Wednesday, reaching $16.85. The company had a trading volume of 1,710,739 shares, compared to its average volume of 1,506,116. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -8.73 and a beta of 1.52. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The firm has a 50-day simple moving average of $19.58 and a 200-day simple moving average of $28.95.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.